George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Violin,
"Why can't LD / Scancell simply proceed with an investment presentation ? Does it need to be tied in with the accounts.."
Those were my thoughts exactly when they postponed first time, even more so the second time.
For those desperate for a live stream from the Final Results Notice RNS:
The Company will also be holding a presentation for investors on 24 October 2023 at 4:30pm BST via the Investor Meet Company platform.
The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event via the Investor Meet Company dashboard up until 9.00am BST on 23 October 2023, or at any time during the live presentation.
To sign up to Investor Meet Company for free and add to register for Scancell's presentation , please visit: https://www.investormeetcompany.com/scancell-holdings-plc/register-investor
Use the link to sign up, it is quick and easy.
Bermuda,
Just to be clear, it was never my intention to suggest or imply any improper behaviour by anyone especially the BOD.
I have always believed that the delay was exactly for the reasons stated in the RNS - I said as much at the time.
Also, I have not suggested that this further patient update in anyway can be interpreted as significant. We await official news on 24th for that.
As to my question around the timing of the post, "is it a coincidence?" , it probably is. The only other possibility I had considered was that the patient was aware official news was due on the 12th had decided off their own back to delay their own account until it could be put in perspective with official analysis. I now know this wasn't the case as the post was made on 10th October, I only spotted it yesterday.
I thought it best to bring the news to the attention of this BB before someone secretly sold up and then started portraying it in a negative light.
Some nice reassuring posts from our more balanced contributors - some very plausible factors in contrast to the conspiracy theorists.
Don't waste the CEO's time, if you don't believe the RNS she's not going to tell you anything different.
WTP, don't let the facts cloud your view!
TF,
Morning to you too.
I always try to be calm, helpful and logical :)
I have for many years now used the TD report as a base for my own projections. Dracula's response was "It's all about a Co making profit Ruck". Well that may be true, but just because a company is yet to make a profit, doesn't mean it has no value. The TD report provide a useful method of valuation in the meantime, ie, before profits or a takeover, either of which should result in a higher SP than the TD valuation (which is why I made the point the TD figure is NOT a "target".
Just because I am positive, doesn't mean I can't accept the possibility of some pretty big downs (temporary one would hope). Just because I feel this has a reduced and acceptable level of risk, doesn't mean it is therefore "no risk". Like I said, I try to be calm, helpful, logical and balanced. It is after all only my opinion so take it or leave it that's your choice.
Dracula,
Totally agree. It should be at least the TD valuation of 30.3p (today).
It looks like people are taking the TD number as a target price. It's not - it is the price you pay today in order to reach a higher target in the future taking into account risk and time. (rNPV = RISK adjusted net PRESENT value) .
So, just holding and waiting should mean an increase in value. (since both time reduces and probability of success increases. This is what has happened if you look at the TD valuations over time - it has gone up in pretty much a straight line:
Date SP
17/11/2020 14.6
14/04/2022 24.0
15/02/2023 27.0
21/02/2023 30.3
If this rate continues, we should see a TD valuation of 40p by this time next year.
I know the actual SP has done strange things but as time and risk reduce I would expect the gap between TD and actual to get narrower.
Rigga,
The needle free delivery system is seen as a big benefit to patients but if there was a cancer cure that could only be delivered by electroporation I think most would go for it - I would! So I don't think that was a particular stumbling block for SCIB and MODI.
It would be an issue for a COVID vaccine which needs many thousands of doses, that would put pharma off covidity if that were the case.
As it is, we are well placed with Pharmajet across all platforms.
GF,
I never said that SCLP would get to 2030. The TD valuation is based on what the products are worth in 2030 in order to calculate the NPV (value today). You can draw a straight line from now to 2030, 30p to £6. As roses points out, in order to get there we will need cash, preferably non-dilutive but if not there will be dilution.
At some point on that straight line graph, a buy out may occur. If that happened today I would expect at LEAST the TD valuation plus a premium. If it happens in a year (when the cash is getting low) I would expect 60p plus a premium. We have little control over that. All we can do is hold on to what we have and buy the dips.